Comoglio PM, Giordano S, Trusolino L (June 2008). "Drug development of MET inhibitors: targeting oncogene addiction and expedience". Nature Reviews Drug Discovery. 7 (6): 504–16. doi:10.1038/nrd2530. PMID18511928. S2CID24601127.
Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R (February 2002). "Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition". Cytokine Growth Factor Rev. 13 (1): 41–59. doi:10.1016/S1359-6101(01)00029-6. PMID11750879.
Porter J, Lumb S, Franklin RJ, Gascon-Simorte JM, Calmiano M, Riche KL, Lallemand B, Keyaerts J, Edwards H, Maloney A, Delgado J, King L, Foley A, Lecomte F, Reuberson J, Meier C, Batchelor M (May 2009). "Discovery of 4-azaindoles as novel inhibitors of c-Met kinase". Bioorg. Med. Chem. Lett. 19 (10): 2780–4. doi:10.1016/j.bmcl.2009.03.110. PMID19369077.
Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C (October 2003), "Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a", Proc. Natl. Acad. Sci. U.S.A., 100 (22): 12654–12659, Bibcode:2003PNAS..10012654S, doi:10.1073/pnas.1734128100, PMC240673, PMID14559966
Christensen JG; Burrows J; Salgia R. (July 2005), "c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention", Cancer Letters, 225 (1): 1–26, doi:10.1016/j.canlet.2004.09.044, PMID15922853
Knudsen BS, Woude GV (February 2008), "Showering c-MET-dependent cancers with drugs", Current Opinion in Genetics & Development, 18 (1): 87–96, doi:10.1016/j.gde.2008.02.001, PMID18406132
Liu XD, Newton RC, Scherle PA (January 2010), "Developing c-MET pathway inhibitors for cancer therapy: progress and challenges", Trends in Molecular Medicine, 16 (1): 37–45, doi:10.1016/j.molmed.2009.11.005, PMID20031486
Kung PP, Funk L, Meng J, Alton G, Padrique E, Mroczkowski B (June 2008), "Structure activity relationships of quinoline-containing c-Met inhibitors", European Journal of Medicinal Chemistry, 43 (8): 1321–1329, doi:10.1016/j.ejmech.2007.08.011, PMID17964000
Bellon SF; Kaplan-Lefko P; Yang YJ; Zhang YH; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I (February 2008), "c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations", Journal of Biological Chemistry, 283 (5): 2675–2683, doi:10.1074/jbc.M705774200, PMID18055465
Dussault I, Bellon SF (February 2009), "From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer", Anti-Cancer Agents in Medicinal Chemistry, 9 (2): 221–229, doi:10.2174/187152009787313792, PMID19199866
Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC (June 2011), "Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197", Journal of Biological Chemistry, 286 (23): 20666–20676, doi:10.1074/jbc.M110.213801, PMC3121448, PMID21454604
Allen JV, Bardelle C, Blades K, Buttar D, Chapman L, Colclough N, Dossetter AG, Garner AP, Girdwood A, Lambert C, Leash AG, Law B, Major J, Plant H, Slater AM (September 2011), "The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach", Bioorganic & Medicinal Chemistry Letters, 21 (18): 5224–5229, doi:10.1016/j.bmcl.2011.07.047, PMID21835616
Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C (October 2003), "Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a", Proc. Natl. Acad. Sci. U.S.A., 100 (22): 12654–12659, Bibcode:2003PNAS..10012654S, doi:10.1073/pnas.1734128100, PMC240673, PMID14559966
Comoglio PM, Giordano S, Trusolino L (June 2008). "Drug development of MET inhibitors: targeting oncogene addiction and expedience". Nature Reviews Drug Discovery. 7 (6): 504–16. doi:10.1038/nrd2530. PMID18511928. S2CID24601127.
Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R (February 2002). "Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition". Cytokine Growth Factor Rev. 13 (1): 41–59. doi:10.1016/S1359-6101(01)00029-6. PMID11750879.
Porter J, Lumb S, Franklin RJ, Gascon-Simorte JM, Calmiano M, Riche KL, Lallemand B, Keyaerts J, Edwards H, Maloney A, Delgado J, King L, Foley A, Lecomte F, Reuberson J, Meier C, Batchelor M (May 2009). "Discovery of 4-azaindoles as novel inhibitors of c-Met kinase". Bioorg. Med. Chem. Lett. 19 (10): 2780–4. doi:10.1016/j.bmcl.2009.03.110. PMID19369077.
Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C (October 2003), "Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a", Proc. Natl. Acad. Sci. U.S.A., 100 (22): 12654–12659, Bibcode:2003PNAS..10012654S, doi:10.1073/pnas.1734128100, PMC240673, PMID14559966
Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang CX, Podar K, Christensen JG, Salgia R (September 2003), "A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase", Cancer Research, 63 (17): 5462–5469, PMID14500382
Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang XY, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JR, Cherrington JM, Mendel DB (November 2003), "A selective small molecule inhibitor of c-Met kinase inhibits c-Met dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo", Cancer Research, 63 (21): 7345–55, PMID14612533
Underiner TL, Herbertz T, Miknyoczki SJ (January 2010), "Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates", Anti-Cancer Agents in Medicinal Chemistry, 10 (1): 7–27, doi:10.2174/1871520611009010007, PMID20015007
Christensen JG; Burrows J; Salgia R. (July 2005), "c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention", Cancer Letters, 225 (1): 1–26, doi:10.1016/j.canlet.2004.09.044, PMID15922853
Knudsen BS, Woude GV (February 2008), "Showering c-MET-dependent cancers with drugs", Current Opinion in Genetics & Development, 18 (1): 87–96, doi:10.1016/j.gde.2008.02.001, PMID18406132
Liu XD, Newton RC, Scherle PA (January 2010), "Developing c-MET pathway inhibitors for cancer therapy: progress and challenges", Trends in Molecular Medicine, 16 (1): 37–45, doi:10.1016/j.molmed.2009.11.005, PMID20031486
Kung PP, Funk L, Meng J, Alton G, Padrique E, Mroczkowski B (June 2008), "Structure activity relationships of quinoline-containing c-Met inhibitors", European Journal of Medicinal Chemistry, 43 (8): 1321–1329, doi:10.1016/j.ejmech.2007.08.011, PMID17964000
Bellon SF; Kaplan-Lefko P; Yang YJ; Zhang YH; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I (February 2008), "c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations", Journal of Biological Chemistry, 283 (5): 2675–2683, doi:10.1074/jbc.M705774200, PMID18055465
Dussault I, Bellon SF (February 2009), "From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer", Anti-Cancer Agents in Medicinal Chemistry, 9 (2): 221–229, doi:10.2174/187152009787313792, PMID19199866
Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC (June 2011), "Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197", Journal of Biological Chemistry, 286 (23): 20666–20676, doi:10.1074/jbc.M110.213801, PMC3121448, PMID21454604
Allen JV, Bardelle C, Blades K, Buttar D, Chapman L, Colclough N, Dossetter AG, Garner AP, Girdwood A, Lambert C, Leash AG, Law B, Major J, Plant H, Slater AM (September 2011), "The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach", Bioorganic & Medicinal Chemistry Letters, 21 (18): 5224–5229, doi:10.1016/j.bmcl.2011.07.047, PMID21835616
Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L, Cristiani C (October 2003), "Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a", Proc. Natl. Acad. Sci. U.S.A., 100 (22): 12654–12659, Bibcode:2003PNAS..10012654S, doi:10.1073/pnas.1734128100, PMC240673, PMID14559966
Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC (June 2011), "Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197", Journal of Biological Chemistry, 286 (23): 20666–20676, doi:10.1074/jbc.M110.213801, PMC3121448, PMID21454604
Comoglio PM, Giordano S, Trusolino L (June 2008). "Drug development of MET inhibitors: targeting oncogene addiction and expedience". Nature Reviews Drug Discovery. 7 (6): 504–16. doi:10.1038/nrd2530. PMID18511928. S2CID24601127.
